ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Wakamoto Pharmaceutical Co., Ltd. ?
1
Poor Management Efficiency with a low ROE of 0.95%
- The company has been able to generate a Return on Equity (avg) of 0.95% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of -6.53% over the last 5 years
3
With a growth in Operating Profit of 903.01%, the company declared Outstanding results in Dec 25
- RAW MATERIAL COST(Y) Fallen by -10.92% (YoY)
- NET SALES(Q) Highest at JPY 2,928.25 MM
- OPERATING PROFIT(Q) Highest at JPY 494.37 MM
4
With ROE of 0.57%, it has a expensive valuation with a 0.91 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 3.22%, its profits have fallen by -54.2%
- At the current price, the company has a high dividend yield of 0.2
5
Underperformed the market in the last 1 year
- The stock has generated a return of 3.22% in the last 1 year, much lower than market (Japan Nikkei 225) returns of 36.73%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Wakamoto Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Wakamoto Pharmaceutical Co., Ltd. for you?
Low Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Wakamoto Pharmaceutical Co., Ltd.
3.22%
1.11
35.05%
Japan Nikkei 225
36.73%
1.30
28.24%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-6.53%
EBIT Growth (5y)
9.03%
EBIT to Interest (avg)
-256.03
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
0.67
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
161.58%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.35%
ROE (avg)
0.95%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
160
Industry P/E
Price to Book Value
0.91
EV to EBIT
-16.75
EV to EBITDA
-279.26
EV to Capital Employed
0.88
EV to Sales
0.98
PEG Ratio
NA
Dividend Yield
0.17%
ROCE (Latest)
-5.23%
ROE (Latest)
0.57%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend31What is working for the Company
RAW MATERIAL COST(Y)
Fallen by -10.92% (YoY
NET SALES(Q)
Highest at JPY 2,928.25 MM
OPERATING PROFIT(Q)
Highest at JPY 494.37 MM
OPERATING PROFIT MARGIN(Q)
Highest at 16.88 %
PRE-TAX PROFIT(Q)
Highest at JPY 398.16 MM
NET PROFIT(Q)
Highest at JPY 349.06 MM
EPS(Q)
Highest at JPY 10.06
-9What is not working for the Company
INTEREST(HY)
At JPY 0.47 MM has Grown at 18.93%
CASH AND EQV(HY)
Lowest at JPY 3,582.99 MM
DEBT-EQUITY RATIO
(HY)
Highest at -12.99 %
Here's what is working for Wakamoto Pharmaceutical Co., Ltd.
Pre-Tax Profit
At JPY 398.16 MM has Grown at 1,640.82%
over average net sales of the previous four periods of JPY 22.87 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (JPY MM)
Net Profit
At JPY 349.06 MM has Grown at 1,835.44%
over average net sales of the previous four periods of JPY 18.03 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (JPY MM)
Net Sales
At JPY 2,928.25 MM has Grown at 40.1%
over average net sales of the previous four periods of JPY 2,090.17 MMMOJO Watch
Near term sales trend is very positive
Net Sales (JPY MM)
Net Sales
Highest at JPY 2,928.25 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (JPY MM)
Operating Profit
Highest at JPY 494.37 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (JPY MM)
Operating Profit Margin
Highest at 16.88 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at JPY 398.16 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (JPY MM)
Net Profit
Highest at JPY 349.06 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (JPY MM)
EPS
Highest at JPY 10.06
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (JPY)
Raw Material Cost
Fallen by -10.92% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Wakamoto Pharmaceutical Co., Ltd.
Interest
At JPY 0.47 MM has Grown at 18.93%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Cash and Eqv
Lowest at JPY 3,582.99 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at -12.99 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
